INR 105.3
(1.4%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 307.12 Million INR | -6.06% |
2022 | 326.92 Million INR | -2.43% |
2021 | 335.07 Million INR | 2.39% |
2020 | 327.27 Million INR | 56.0% |
2019 | 209.78 Million INR | -7.68% |
2018 | 227.24 Million INR | -5.22% |
2017 | 239.75 Million INR | -45.79% |
2016 | 442.25 Million INR | -12.22% |
2015 | 503.8 Million INR | 20.67% |
2014 | 417.48 Million INR | 8.71% |
2013 | 384.04 Million INR | 23.47% |
2012 | 311.04 Million INR | -3.34% |
2011 | 321.79 Million INR | -0.02% |
2010 | 321.85 Million INR | -26.77% |
2009 | 439.52 Million INR | -30.32% |
2008 | 630.8 Million INR | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | -1.51 Billion INR | -594.62% |
2023 Q1 | - INR | -100.0% |
2023 Q4 | 307.12 Million INR | 0.0% |
2023 Q3 | - INR | -100.0% |
2023 Q2 | 405.84 Million INR | 0.0% |
2023 FY | 307.12 Million INR | -6.06% |
2022 Q1 | - INR | -100.0% |
2022 Q2 | 427.8 Million INR | 0.0% |
2022 Q3 | - INR | -100.0% |
2022 FY | 326.92 Million INR | -2.43% |
2022 Q4 | 326.92 Million INR | 0.0% |
2021 Q4 | 335.07 Million INR | 0.0% |
2021 FY | 335.07 Million INR | 2.39% |
2021 Q1 | - INR | -100.0% |
2021 Q2 | 258.45 Million INR | 0.0% |
2021 Q3 | - INR | -100.0% |
2020 FY | 327.27 Million INR | 56.0% |
2020 Q1 | - INR | -100.0% |
2020 Q3 | - INR | -100.0% |
2020 Q2 | 262.12 Million INR | 0.0% |
2020 Q4 | 327.27 Million INR | 0.0% |
2019 FY | 209.78 Million INR | -7.68% |
2019 Q3 | - INR | -100.0% |
2019 Q4 | 209.78 Million INR | 0.0% |
2019 Q1 | - INR | -100.0% |
2019 Q2 | 197.92 Million INR | 0.0% |
2018 Q4 | 227.24 Million INR | 0.0% |
2018 FY | 227.24 Million INR | -5.22% |
2018 Q1 | - INR | 0.0% |
2017 FY | 239.75 Million INR | -45.79% |
2016 FY | 442.25 Million INR | -12.22% |
2015 Q2 | 304.92 Million INR | 0.0% |
2015 FY | 503.8 Million INR | 20.67% |
2014 Q1 | - INR | -100.0% |
2014 FY | 417.48 Million INR | 8.71% |
2014 Q3 | - INR | -100.0% |
2014 Q2 | 361.12 Million INR | 0.0% |
2014 Q4 | 417.48 Million INR | 0.0% |
2013 Q1 | - INR | -100.0% |
2013 FY | 384.04 Million INR | 23.47% |
2013 Q3 | - INR | -100.0% |
2013 Q2 | 382.84 Million INR | 0.0% |
2013 Q4 | 384.04 Million INR | 0.0% |
2012 FY | 311.04 Million INR | -3.34% |
2012 Q4 | 311.04 Million INR | 0.0% |
2011 FY | 321.79 Million INR | -0.02% |
2011 Q4 | 321.79 Million INR | 0.0% |
2010 FY | 321.85 Million INR | -26.77% |
2009 FY | 439.52 Million INR | -30.32% |
2008 FY | 630.8 Million INR | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Alembic Pharmaceuticals Limited | 16.27 Billion INR | 98.113% |
Aurobindo Pharma Limited | 152.2 Billion INR | 99.798% |
Glenmark Life Sciences Limited | 5.18 Billion INR | 94.072% |
Granules India Limited | 22.95 Billion INR | 98.662% |
Indoco Remedies Limited | 10.34 Billion INR | 97.03% |
Achyut Healthcare Limited | 2.01 Million INR | -15156.93% |
Ajanta Pharma Limited | 10.71 Billion INR | 97.132% |
Alkem Laboratories Limited | 48.6 Billion INR | 99.368% |
Brooks Laboratories Limited | 248.6 Million INR | -23.54% |
AstraZeneca Pharma India Limited | 3.66 Billion INR | 91.611% |
Bajaj HealthCare Limited | 4.86 Billion INR | 93.691% |
Bliss GVS Pharma Limited | 2.1 Billion INR | 85.437% |
Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 99.713% |
Eris Lifesciences Limited | 38.26 Billion INR | 99.197% |
FDC Limited | 3.7 Billion INR | 91.72% |
Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 99.528% |
Gufic Biosciences Limited | 5.59 Billion INR | 94.515% |
Ind-Swift Laboratories Limited | 2.28 Billion INR | 86.585% |
Ipca Laboratories Limited | 33.74 Billion INR | 99.09% |
Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -3.492% |
Krebs Biochemicals & Industries Limited | 2.97 Billion INR | 89.673% |
Lasa Supergenerics Limited | 541.92 Million INR | 43.328% |
Laurus Labs Limited | 42.71 Billion INR | 99.281% |
Lupin Limited | 96.23 Billion INR | 99.681% |
Mankind Pharma Limited | 23.87 Billion INR | 98.714% |
Medicamen Biotech Limited | 940.36 Million INR | 67.34% |
Medico Remedies Limited | 438.24 Million INR | 29.92% |
Megasoft Limited | 1.85 Billion INR | 83.427% |
NATCO Pharma Limited | 10.53 Billion INR | 97.084% |
Piramal Pharma Limited | 74 Billion INR | 99.585% |
RPG Life Sciences Limited | 1.38 Billion INR | 77.748% |
Sigachi Industries Limited | 2.53 Billion INR | 87.867% |
Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 99.833% |
Suven Pharmaceuticals Limited | 2.03 Billion INR | 84.902% |
Syncom Formulations (India) Limited | 1.16 Billion INR | 73.642% |
Unichem Laboratories Limited | 8.06 Billion INR | 96.194% |
Wanbury Limited | 3.15 Billion INR | 90.267% |
Windlas Biotech Limited | 1.76 Billion INR | 82.577% |
ZIM Laboratories Limited | 2.08 Billion INR | 85.24% |
Zydus Lifesciences Limited | 71.79 Billion INR | 99.572% |
Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | 92.111% |
Divi's Laboratories Limited | 18.99 Billion INR | 98.383% |
Hester Biosciences Limited | 3.59 Billion INR | 91.456% |
Procter & Gamble Health Limited | 2.56 Billion INR | 88.009% |
Amrutanjan Health Care Limited | 783.82 Million INR | 60.817% |
Bal Pharma Limited | 2.51 Billion INR | 87.77% |
Strides Pharma Science Limited | 37.68 Billion INR | 99.185% |
Venus Remedies Limited | 1.39 Billion INR | 77.949% |
Aarti Pharmalabs Limited | 8.25 Billion INR | 96.278% |
Nectar Lifesciences Limited | 11.21 Billion INR | 97.262% |
Shilpa Medicare Limited | 12.93 Billion INR | 97.625% |
Aarti Drugs Limited | 11.5 Billion INR | 97.33% |
IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | 95.147% |
Suven Life Sciences Limited | 148.62 Million INR | -106.648% |
Ind-Swift Limited | 13.45 Billion INR | 97.717% |
Valiant Laboratories Limited | 1.05 Billion INR | 70.979% |
J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | 97.132% |
Solara Active Pharma Sciences Limited | 14.14 Billion INR | 97.829% |
Themis Medicare Limited | 1.88 Billion INR | 83.729% |
Hikal Limited | 12.99 Billion INR | 97.637% |
Torrent Pharmaceuticals Limited | 82.05 Billion INR | 99.626% |
Sequent Scientific Limited | 8.27 Billion INR | 96.288% |
Novartis India Limited | 1.8 Billion INR | 82.948% |
Wockhardt Limited | 39.87 Billion INR | 99.23% |
Jubilant Pharmova Limited | 61.27 Billion INR | 99.499% |
Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -6.345% |
Neuland Laboratories Limited | 5.49 Billion INR | 94.415% |
Morepen Laboratories Limited | 4.45 Billion INR | 93.114% |
Kilitch Drugs (India) Limited | 643.88 Million INR | 52.302% |
Mangalam Drugs & Organics Limited | 1.97 Billion INR | 84.46% |